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Treatment decisions after diagnosis of clinically localised prostate cancer are difficult due to variability in tumour behaviour. We
therefore examined one of the most promising biomarkers in prostate cancer, Ki-67, in a cohort of 808 patients diagnosed with
prostate cancer between 1990 and 1996 and treated conservatively. Ki-67 expression was assessed immunohistochemically, in two
laboratories, by two different scoring methods and the results compared with cancer-specific and overall survival. The power of the
biomarker was compared with Gleason score and initial serum prostate-specific antigen (PSA). Both methods showed that Ki-67
provided additional prognostic information beyond that available from Gleason score and PSA: for the semi-quantitative method,
Dw2 (1 d.f.)¼ 24.6 (Po0.0001), overall survival w2¼ 20.5 (Po0.0001), and for the quantitative method, Dw2 (1 d.f.)¼ 15.1
(P¼ 0.0001), overall survival w2¼ 10.85 (P¼ 0.001). Ki-67 is a powerful biomarker in localised prostate cancer and adds to a model
predicting the need for radical or conservative therapy. As it is already in widespread use in routine pathology, it is confirmed as the
most promising biomarker to be applied into routine practice.
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In spite of extensive research, there are very few molecular
markers that have been translated into routine use in
clinical oncology. Any new biomarker must give further predictive
ability beyond that available by using current known,
easily measured parameters, and the data must differentiate
patients into groups for which different treatment options can be
selected. Biomarker measurement for purely prognostic informa-
tion has limited utility unless it indicates different treatment
options.
In no area of oncology are new biomarkers more urgently
required than in prostate cancer. The most appropriate treatment
for clinically localised prostate cancer is still unknown. Treatment
options vary from radical surgery (Bott et al, 2005) or radiotherapy
(Parker and Dearnaley, 2003) to hormonal treatment alone, or
simply active surveillance and watchful waiting (Albertsen et al,
2005; Parker et al, 2006). Patients must choose, with little
scientific rationale, between these wildly contrasting treatments.
Screening for prostate cancer in the United States has caused
an almost doubling incidence, whereas mortality has remained
relatively stable (McDavid et al, 2004). Radical treatments have
the advantage of a high cure rate. However, this comes with the
potential of serious long-term morbidity from sexual dysfunction
or incontinence. Many tumours do not need such radical
intervention, given that the majority of men die ‘with’ their
prostate cancer rather than ‘from’ it. A more conservative
approach with regular monitoring of clinical parameters, such
as serum prostate-specific antigen (PSA) and possibly rebiopsy
and intervention if necessary, has become a viable treatment
option (Parker et al, 2006), but 20–30% of men on active
surveillance go on to receive radical treatments, and to select the
appropriate patient for this management strategy remains a
challenge.
Although Gleason score and serum PSA have been shown to be
strong predictors of prognosis in early prostate cancer, much
remains to be done to improve predictions. There remains a
middle range of prostatic tumours (Gleason score o7 and low
PSA), where it is not possible with current methods to predict
recurrence. The search for biomarkers that can add to the
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knowledge provided by the known markers is therefore of high
importance in future as a guide to therapy.
The Ki-67 protein is well known and widely used to assess the
tumour proliferation rate. It is one of the several cell-cycle-
regulating proteins, which can be demonstrated by immuno-
histochemistry (Gerdes et al, 1983). It is a DNA-binding protein
that is expressed in all phases of cell cycle but undetectable in
resting cells (Gerdes et al, 1991) though strangely its function is yet
to be clearly elucidated. Numerous studies have shown Ki-67 to be
a prognostic marker in prostate cancer treated by radical
prostatectomy, but none in a large conservatively treated cohort
of prostate cancers with long-term follow-up in which clear relative
risk values can be calculated. Our hypothesis was that measure-
ment of Ki-67 in such a well-defined cohort could provide
prognostic information that supplemented the currently known
indicators of prognosis in prostate cancer.
MATERIALS AND METHODS
The Trans-Atlantic Prostate Group (TAPG) of clinicians and
scientists from the United States and the United Kingdom have
assembled the largest cohort of prostate cancers treated by
conservative means with both initial serum PSA levels and
centralised Gleason scoring. The detailed methods of cohort
assembly have been described in an earlier paper (Cuzick et al,
2006). In short, men were included in this study if they were under
76 years of age at diagnosis and had clinically localised prostate
cancer diagnosed between January 1990 and December 1996.
Patients who had a radical prostatectomy or radiation therapy
within 6 months of diagnosis, or clear evidence of metastatic
disease (by bone scan, X-ray, CT scan, MRI, bone biopsy, lymph
node biopsy or pelvic lymph node dissection) or clinical
indications of metastatic disease (including pathologic fracture,
soft tissue metastasis, spinal compression or bone pain) at or
within 6 months of diagnosis, were excluded. Eligibility was
established by review of patient records by registry data-collection
officers and trained medical staff. Clinical staging was centrally
reviewed. All patients had centralised Gleason grading by a panel
of genitourinary pathologists and had initial diagnostic serum PSA
available. Blocks from the trans-urethral resection specimens,
which were available, were identified and the corresponding
haematoxylin and eosin sections marked for cancerous areas.
These were microarrayed in a series of 24 blocks using 0.6 mm
cylinders of tissue. Four cores were taken from different areas of
tumour to account for tumour heterogeneity in each case, and
areas of adjacent normal tissue were also sampled.
The sections were immunostained for Ki-67 using DAKO (MIBI,
Carpinteria, CA, USA), with an overnight incubation at 41C, 1 : 200
dilution and pretreatment with citric acid, pH 6.0. Immunostaining
for p63 and CK5/6 were also performed to ensure that only
cancerous areas were identified when the cores were examined.
These are immunohistochemical markers of prostatic basal cells
and are absent in areas of prostatic carcinoma. Normal tonsil was
used as a positive control where a high proliferation is seen in
germinal centres.
The samples were all examined in a semi-quantitative manner
(DB/SK) giving each tumour core an estimated percentage of
positive cells, in a manner similar to that used in routine pathology
departments for the assessment of proliferation index in other
organs. A more formalised quantitative approach was also
undertaken (AG/WG). Slides were scanned at  4 for any nuclear
staining. A magnification of  10 was used to verify that the
staining was in carcinoma. The total number of carcinoma cells in
a given core was estimated at  10 and estimated as low,
intermediate or high cellularity corresponding to p99, 100–299
and X300 cells (number of cells was recorded as multiples of 25).
The number of Ki-67-positive cells was then individually counted
at  10 magnification. A percentage was derived using the number
of Ki-67-positive cells as the numerator and the total number of
malignant cells (invasive carcinoma) as the denominator. Estima-
tion of Ki-67 positivity was not carried out when thermal/crush
artefact precluded evaluation of individual cells. In common with
other microarray studies, the maximal staining from the sampled
cores for each case was taken. For each patient, the maximum
value of Ki-67 % staining in all cancerous cores was calculated and
used for analysis. The results were analysed by dichotomous,
grouped and continuous variables and compared with overall and
prostate cancer-specific survival. The effect of Ki-67 was evaluated
by multivariate comparisons in a model including Gleason score,
serum PSA and extent of disease and with ETS (ERG–ETV1 fusion
gene rearrangement) status.
RESULTS
A total of 808 eligible cases were included on the tissue microarray.
Their derivation is described in Figure 1. Ki-67 staining results
were analysed for both the semi-quantitative and quantitative
methods.
Analysis included 1798 Ki-67-stained cancerous cores, corre-
sponding to 693 cases. Characteristics of the cohort are given in
Table 1.
The mean Ki-67 score was 5.42%, with a standard deviation of
6.98% and a range of 0 –60% (Figure 2).
The prognostic value of Ki-67, as a biomarker for prostate
cancer-specific and overall survival, was assessed as a continuous
variable, as a grouped variable with limits 0, 1, 5, 10, 410– 100 and
as a dichotomous variable with a cutoff at p5%.
In univariate analysis, the most useful variable was Gleason
score (w2(trend)¼ 164), followed by extent of the disease, Ki-67,
baseline PSA, clinical stage and ETS status. The discriminating
power of age (w2(trend)¼ 4) and year of diagnosis (w2(trend)¼ 6.2)
was low. Results were similar to those reported for the total cohort.
Gleason score was the most informative variable (w2(trend)
¼ 164), but the extent of disease appeared a stronger variable
than baseline PSA (w2(trend)¼ 116 and 87, respectively). The level
of Ki-67 staining was a significant prognostic factor for cause-
specific survival (HR¼ 1.09, 95% CI¼ 1.07–1.10, Po0.001) and
overall survival (HR¼ 1.06, 95% CI¼ 1.05–1.07, Po0.001).
Significance was maintained whether the results were analysed as
a continuous variable or as groups (Table 1; Figure 3A and B). A
more fully quantitative method assessed by counting cells (AG and
WG) did not improve the predictive value (Table 1).
The three strongest variables, Gleason score, baseline PSA and
extent of disease, were included in a multivariate model together
with Ki-67. Results for all four variables were available for 685
cases (99%). The level of Ki-67 staining remained an independent
prognostic factor of cause-specific survival (Dw2 (1 d.f.)¼ 24.6,
Po0.0001) and overall survival (w2¼ 20.5, Po0.0001) (Table 2).
Again, the use of a more fully quantitative method was not better
than the semi-quantitative method reported in this table (details
not shown).
ERG–ETV1 rearrangement status has been shown to be an
important predictor for prostate cancer cause-specific survival. In
univariate analysis, the presence or absence of ETS was significant
for cause-specific survival (HR¼ 2.38, 95% CI¼ 1.7–3.3,
Po0.0001). However, ETS status was not significant independently
of Gleason score, PSA and extent of disease in multivariate analysis
(Dw2 (1 d.f.)¼ 0.64, P¼ 0.42).
We evaluated Ki-67 in both ETS-positive and ETS-negative
subsets and found similar predictive values in both subgroups (HR
1.32, 95% CI 1.0–1.7, vs 1.61, 95% CI 1.2–2.2, respectively), and
the test for heterogeneity was not significant (P¼ 0.5).
In subgroups based on Gleason score, the independent
prognostic significance of Ki-67 for cause-specific survival was
Ki-67 in conservatively treated prostate cancer
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maintained in men with Gleason score 47 (Po0.0001), but not in
men with Gleason score p7, and similarly for overall survival,
in men with Gleason score 47 (P¼ 0.0003) (Table 2).
In risk groups using Gleason score and baseline PSA, identified
earlier as high (prostate cancer mortality at 10 years 430%),
intermediate and low risk (prostate cancer mortality at 10 years
o10%), Ki-67 was a significant independent prognostic factor for
cause-specific survival in men at high risk (P¼ 0.0001) or
intermediate risk (P¼ 0.049), but not among those at low risk of
dying from prostate cancer, possibly because of the very few cases
of men with a low Gleason score and high Ki-67 (P¼ 0.99).
DISCUSSION
Thousands of patients undergo radical treatment for prostate
cancer every year in Europe and the United States. Many of these
patients will have curative and beneficial treatment. However, a
significant number of these patients have treatment unnecessarily
as their tumours will not progress before death from another
cause. They may suffer unnecessary morbidity from their surgery.
This was recognised in the recently published National Institute
of Clinical Excellence (NICE) prostate cancer guidelines in the
United Kingdom, which states under its key research recommen-
dations that ‘Further research is required into the identification of
prognostic indicators in order to differentiate effectively between
men who may die with prostate cancer and those who might die
from prostate cancer. The greatest uncertainties in managing
prostate cancer are around the identification of which cancers are
of clinical significance and over the choice of radical treatment,
and in which settings they are appropriate. With the diagnosis of
prostate cancer being made more frequently in asymptomatic men,
it is of growing importance to know which of these men are likely
to benefit from aggressive treatment.’ (http://www.nice.org.uk/
nicemedia/pdf/CG58FullGuideline.pdf, 2008).
Numerous studies have shown Ki-67 to be a prognostic
indicator in various stages of prostate cancer. However, to our
knowledge, there are no studies conducted on a large conserva-
tively treated cohort with outcome data, where decisions on future
treatment could be indicated, and a very recent paper (Laurila
et al, 2009) suggested that further studies are needed to show the
final outcome of proliferative activity in patients with watchful
waiting.
Since the initial studies showing the utility and feasibility
of immunochemistry on paraffin-embedded formalin-fixed uro-
logical material (Fontana et al, 1987), Ki-67 was shown to be an
interesting marker in prostate cancer at an early stage (Oomens
et al, 1991; McLoughlin et al, 1993). It has been investigated on
TURP material (Feneley et al, 1996), biopsy material (Szende et al,
1999; Cowen et al, 2002; Ojea et al, 2004) and radical
prostatectomy series (Bettencourt et al, 1996; Moul, 1999; Zudaire
Bergera et al, 2000; Inoue et al, 2005) in large screening
programmes (Laurila et al, 2009) and after radiation therapy
(Li et al, 2004). Some of these show that Ki-67 is an independent
predictor of outcome on multivariate analysis (Pollack et al, 2004).
This is the largest series to date with marker analysis and one that
utilises the currently used prognostic biomarkers of serum PSA
and Gleason score. This is of great relevance as all of these cancers
were treated conservatively at diagnosis, and therefore the Ki-67
score would have given further information on recurrence risk and
enhanced the decision making process of radical vs conservative
management. Our earlier papers on this cohort have shown the
discriminatory value of revised Gleason score and serum PSA at
predicting tumour behaviour (Cuzick et al, 2006; Kattan et al,
2007; Eastham et al, 2008). However, the natural history of 60% of
the cohort, where the Gleason score was 6 or 7 and with moderate
PSA rises, was in doubt.
Ki-67 has a number of advantages as a biomarker. First, it is
widely used by academic and non-academic Histopathology
departments, which have the ability to perform immunochemistry,
N (%)
Cases not requested 203 (9) 
Excluded on review:
Unknown, missing histology slides 284 (12)
Incorrect pathology specimen 43 (2) 
  Histologically negative 135 (6) 
  No histology tissue left in block 6 (<1) 
  Histologically ungradeable Gleason score 6 (<1) 
Eligible patients 
n = 2333 
Cases with reviewed 
histology and assigned 
Gleason score n = 1656 
Cases diagnosed by TURP 
             n = 909 
Cases diagnosed by needle biopsy 
n = 796 (45%) 
Blocks not retrieved n = 89 (10%) 
Blocks with inadequate tumour n = 8 (1%) 
Blocks mismatched n = 4 (<1%)
Cases on Tissue micro array 
n = 808 (3959 cores) 
Figure 1 Tissue microarray cohort derivation.
Ki-67 in conservatively treated prostate cancer
DM Berney et al
890
British Journal of Cancer (2009) 100(6), 888 – 893 & 2009 Cancer Research UK
C
lin
ic
a
l
S
tu
d
ie
s
and is used as an adjunct to diagnosis and management in a
number of other diseases. It is easily verified in control tissue and
it is very easy to measure in a semi-quantitative manner, similar to
‘quick scores’ performed for receptor status in breast cancers. This
study shows that semi-quantitative methodologies may produce as
much information as more time-consuming methods that may not
be possible for the average laboratory. Immunochemistry has the
advantage over other molecular techniques that it is easily applied
to paraffin-embedded tissue and has a very low ‘failure’ rate,
unlike fluorescence. The TAPG group has shown in an earlier
paper that fluorescence in situ hybridisation for the detection of
the TMPSS/ERG translocation also identifies aggressive prostate
cancer (Attard et al, 2008). However, such assessments can be
difficult with small amounts of formalin-fixed material, and the
recent discovery of complex rearrangements within single glands
raises problems with tumour heterogeneity (Clark et al, 2008).
These techniques are not available in most hospitals, and need
careful assessment. Tumour tissue from the prostate is very
difficult to identify macroscopically, and therefore assessment in
Table 1 Univariate analysis of factors influencing death from prostate
cancer in men with conservatively managed clinically localised prostate
cancer: total cohort (n¼ 693)
Variable N (%) Hazard ratio (95% CI)
Gleason scorea
p5 30 (4) 0.34 (0–2.5)
6 306 (44) 1b
7 183 (26) 3.25 (2.1–5.1)
8 86 (12) 5.58 (3.4–9.1)
9 or 10 88 (13) 14.56 (9.3–22.7)
w2(trend)¼ 164
Serum PSA (ng ml1)
p4 233 (34) 1b
44–10 139 (20) 2.13 (1.2–3.7)
410–25 148 (21) 4.31 (2.6–7.2)
425–50 107 (15) 5.6 (3.4–9.4)
450–100 66 (10) 8.77 (5.1–15)
w2(trend)¼ 87
Clinical stage
T1 189 (27) 1b
T2 160 (23) 2.87 (1.7–4.8)
T3 80 (12) 5.83 (3.4–9.9)
Unknownc 264 (38)
w2(trend)¼ 45
Cancer in biopsy (%)
p6 166 (24) 0.77 (0.4–1.5)
46–20 172 (25) 1b
420–40 102 (15) 2.47 (1.4–4.5)
440–75 103 (15) 4.04 (2.3–7)
475–100 142 (20) 6.66 (4.1–10.9)
Unspecifiedc 8 (1)
w2(trend)¼ 116
Ki-67 % groups (semi-quantitative)
0–1 303 (44) 1b
41–5 232 (33) 1.59 (1.1–2.4)
45–10 99 (14) 3.60 (2.3–5.5)
410–100 59 (9) 9.25 (6–14.2)
w2(trend)¼ 97
Ki-67% class (semi-quantitative)
0–5 535 (77) 1b
45 158 (23) 4.17 (3.1–5.6)
w2(trend)¼ 78
Ki-67 % groups (quantitative)d
0–1 72 (11) 1b
41–5 240 (36) 1.08 (0.6–2.0)
45–10 171 (25) 1.17 (0.6–2.3)
410–100 188 (28) 3.52 (1.9–6.4)
w2(trend)¼ 45
Ki-67% class (quantitative)d
0–5 312 (46) 1b
45 359 (54) 2.14 (1.6–2.9)
w2(trend)¼ 24
CI¼ confidence interval; PSA¼ prostate-specific antigen. aScore assigned during
histopathological review. bReference category. cThese cases were excluded from the
trend analysis. dQuantitative method: total cohort (n¼ 671).
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Figure 2 Distribution of Ki-67 % staining in cases, n¼ 693.
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this manner remains by far the simplest technique by which tissue
biomarker assessment is likely to become widespread in the
assessment of prostatic malignancy. From a biological point of
view, Ki-67 use as a proliferation marker is also an adjunct to
existing methods. Although many grading systems for cancers
include mitotic count in the calculation of grade (such as the
Nottingham method for assessing grade in breast carcinoma), the
Gleason grading system is purely pattern based. Therefore, this
may be a reason why the estimation of proliferation index appears
such a powerful independent predictor of tumour behaviour. The
other cardinal advantage of this cohort is the length of follow-up
and the use of both cause-specific and overall death outcomes. The
natural history of prostate cancer means that such long-term
assessments are essential for the validation of new biomarkers.
A number of limitations of the study have to be noted. First, this
is a retrospective cohort study dealing with prostate cancer
diagnosis, as it was in the 1990s rather than it is presently. Most
patients would have presented symptomatically, and the vast
increase in prostate cancer diagnosis in the past 20 years is
undoubtedly due to an increase in PSA screening. However, in all
countries, prostate cancer diagnosis continues to be unscientific in
its basis. Screening is unproven and instituted in relatively few
centres. Health-care standards in the United States vary from
intense screening, with a high cancer detection of clinically
insignificant tumours in centres of excellence, to more symptom-
based treatments in the disadvantaged parts of the population.
In the United Kingdom, there has been an increase in requests
for PSA testing, but many men are only tested after complaining of
urinary symptoms. Thus, despite an increase in public health
awareness of prostate cancer, the disease is detected by a variety of
methods, and we have moved from one unscientifically proven
model to another, which is equally unproven. Screening, although
popular politically, is not evidence based in prostate cancer.
Hardly one criterion for screening assessment is fulfilled by
prostate cancer. The medical community is therefore left with
offering patients a variety of drastically different treatments,
with no evidence base.
However, the major difference between this study and current
practice is that it is an assessment of TURP material only. As
biopsy diagnosis of prostate cancer is far more common, especially
in developed countries, it could be argued that this study does not
represent modern detection methods. The original cohort com-
prised 55% TURP and 45% biopsy-diagnosed tumours. Interest-
ingly, the method of diagnosis had no significant difference on
outcome in our cohort (Cuzick et al, 2006), and Gleason profiles of
both limbs were comparable. The assessment of Ki-67 on the
biopsy material, which forms the second half of this cohort, is
planned to further validate these data, as well as computer-based
assessments of Ki-67 index, to attempt validation of systems that
can be used in different laboratories.
Despite intense interest, no biomarker is currently routinely
utilised for the assessment of the degree of aggressiveness of
prostate cancer. We have shown that Ki-67 is an interesting
candidate for the routine assessment of suitability for active
surveillance treatments and that this study needs to be confirmed
in biopsy material.
ACKNOWLEDGEMENTS
This study was supported by Cancer Research UK, The National
Institute of Health (SPORE), The Koch Foundation, The NCRI and
the Grand Charity of Freemasons and The Orchid Appeal.
REFERENCES
Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following
conservative management of clinically localized prostate cancer. JAMA
293: 2095 – 2101
Attard G, Clark J, Ambroisine L, Fisher G, Kovacs G, Flohr P, Berney D,
Foster CS, Fletcher A, Gerald WL, Moller H, Reuter V, De Bono JS,
Scardino P, Cuzick J, Cooper CS (2008) Duplication of the fusion of
TMPRSS2 to ERG sequences identifies fatal human prostate cancer.
Oncogene 27: 253 – 263
Bettencourt MC, Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG,
Moul JW (1996) Ki-67 expression is a prognostic marker of
prostate cancer recurrence after radical prostatectomy. J Urol 156:
1064 – 1068
Bott SR, Freeman AA, Stenning S, Cohen J, Parkinson MC (2005) Radical
prostatectomy: pathology findings in 1001 cases compared with other
major series and over time. BJU Int 95: 34 – 39
Clark J, Attard G, Jhavar S, Flohr P, Reid A, De-Bono J, Eeles R, Scardino P,
Cuzick J, Fisher G, Parker MD, Foster CS, Berney D, Kovacs G, Cooper
CS (2008) Complex patterns of ETS gene alteration arise during cancer
development in the human prostate. Oncogene 27: 1993 – 2003
Cowen D, Troncoso P, Khoo VS, Zagars GK, von Eschenbach AC, Meistrich
ML, Pollack A (2002) Ki-67 staining is an independent correlate of
biochemical failure in prostate cancer treated with radiotherapy. Clin
Cancer Res 8: 1148 – 1154
Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Moller H,
Reuter V, Fearn P, Eastham J, Scardino P (2006) Long-term outcome
among men with conservatively treated localised prostate cancer.
Br J Cancer 95: 1186 – 1194
Eastham JA, Kattan MW, Fearn P, Fisher G, Berney DM, Oliver T, Foster
CS, Moller H, Reuter V, Cuzick J, Scardino P (2008) Local progression
among men with conservatively treated localized prostate cancer: results
from the transatlantic prostate group. Eur Urol 53: 347 – 351
Feneley MR, Young MP, Chinyama C, Kirby RS, Parkinson MC (1996) Ki-67
expression in early prostate cancer and associated pathological lesions.
J Clin Pathol 49: 741 – 748
Fontana D, Bellina M, Valente G, Fasolis G, Colombo M, Dublino M, Rolle
L, Porpiglia F (1987) Use of the monoclonal antibody KI-67 in the study
of the proliferative activity of urologic tumors. Preliminary data. J Urol
(Paris) 93: 549 – 552
Table 2 The added value of Ki-67 in a multivariate model for prostate
cancer-specific survival and overall survival, based on gleason grade,
baseline PSA, percentage cancer in biopsy and Ki-67: Ki-67 staining was
measured semi-quantitatively: total cohort (n¼ 685)
Prostate cancer survival Overall survival
Added
variable Deaths
Dw2
(1 d.f.) P-value Deaths
Dw2
(1 d.f.) P-value
Ki-67 % (continuous) 173 24.55 o0.0001 418 20.52 o0.0001
Ki-67 % (groups) 173 18.55 o0.0001 418 11.97 0.0005
Ki-67 % (p5, 45) 173 13.41 0.0003 418 10.42 0.0012
Gleasono7
Ki-67 % (groups) 31 0.01 0.91 153 1.11 0.29
Gleason¼ 7
Ki-67 % (groups) 48 2.02 0.15 125 1.02 0.31
Gleason47
Ki-67 % (groups) 94 20.63 o0.0001 140 13.15 0.0003
PSA¼ prostate-specific antigen.
Ki-67 in conservatively treated prostate cancer
DM Berney et al
892
British Journal of Cancer (2009) 100(6), 888 – 893 & 2009 Cancer Research UK
C
lin
ic
a
l
S
tu
d
ie
s
Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, Stahmer
I, Kloth S, Brandt E, Flad HD (1991) Immunobiochemical and molecular
biologic characterization of the cell proliferation-associated nuclear
antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 138:
867 – 873
Gerdes J, Schwab U, Lemke H, Stein H (1983) Production of a mouse
monoclonal antibody reactive with a human nuclear antigen associated
with cell proliferation. Int J Cancer 31: 13 – 20
http://www.nice.org.uk/nicemedia/pdf/CG58FullGuideline.pdf 2008. Ref Type:
Data File
Inoue T, Segawa T, Shiraishi T, Yoshida T, Toda Y, Yamada T, Kinukawa N,
Kinoshita H, Kamoto T, Ogawa O (2005) Androgen receptor, Ki67, and
p53 expression in radical prostatectomy specimens predict treatment
failure in Japanese population. Urology 66: 332 – 337
Kattan MW, Cuzick J, Fisher G, Berney DM, Oliver T, Foster CS,
Moller H, Reuter V, Fearn P, Eastham J, Scardino PT (2007) Nomogram
incorporating PSA level to predict cancer-specific survival for men with
clinically localized prostate cancer managed without curative intent. Cancer
112: 69 – 74
Laurila M, Tammela TL, Auvinen A, Isola J, Visakorpi T, Luukkaala T,
Maattanen L, Ruutu M, la-Opas M, Mildh M, Martikainen P (2009)
Biological aggressiveness of prostate cancer in the Finnish screening
trial. Int J Cancer 124: 547 – 552
Li R, Heydon K, Hammond ME, Grignon DJ, Roach III M, Wolkov HB,
Sandler HM, Shipley WU, Pollack A (2004) Ki-67 staining index predicts
distant metastasis and survival in locally advanced prostate cancer
treated with radiotherapy: an analysis of patients in radiation therapy
oncology group protocol 86-10. Clin Cancer Res 10: 4118 – 4124
McDavid K, Lee J, Fulton JP, Tonita J, Thompson TD (2004) Prostate cancer
incidence and mortality rates and trends in the United States and
Canada. Public Health Rep 119: 174 – 186
McLoughlin J, Foster CS, Price P, Williams G, Abel PD (1993) Evaluation of
Ki-67 monoclonal antibody as prognostic indicator for prostatic
carcinoma. Br J Urol 72: 92 – 97
Moul JW (1999) Angiogenesis, p53, bcl-2 and Ki-67 in the progression of
prostate cancer after radical prostatectomy. Eur Urol 35: 399 – 407
Ojea CA, Mosteiro Cervino MJ, Dominguez FF, Alonso RA, Rodriguez IB,
Benavente DJ, Barros Rodriguez JM, Gonzalez PA (2004) The usefulness
of Ki67 expression in the biopsy specimens, to predict the biochemical
progression of the prostate cancer after radical prostatectomy. Actas Urol
Esp 28: 650 – 660
Oomens EH, van Steenbrugge GJ, van der Kwast TH, Schroder FH (1991)
Application of the monoclonal antibody Ki-67 on prostate biopsies to
assess the fraction of human prostatic carcinoma. J Urol 145: 81 – 85
Parker C, Muston D, Melia J, Moss S, Dearnaley D (2006) A model of the
natural history of screen-detected prostate cancer, and the effect of
radical treatment on overall survival. Br J Cancer 94: 1361 – 1368
Parker CC, Dearnaley DP (2003) Radical radiotherapy for prostate cancer.
Cancer Treat Rev 29: 161 – 169
Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME,
Venkatesan V, Lawton CA, Roach III M, Shipley WU, Hanks GE, Sandler
HM (2004) Ki-67 staining is a strong predictor of distant metastasis and
mortality for men with prostate cancer treated with radiotherapy plus
androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.
J Clin Oncol 22: 2133 – 2140
Szende B, Romics I, Torda I, Bely M, Szegedi Z, Lovasz S (1999) Apoptosis,
mitosis, p53, bcl(2), Ki-67 and clinical outcome in prostate carcinoma
treated by androgen ablation. Urol Int 63: 115 – 119
Zudaire Bergera JJ, Sanchez ZD, rocena Garcia-Tapia J, Sanz PG, Diez CF,
Lopez FJ, Rosell CD, Robles Garcia JE, de AE, Berian Polo JM (2000) [p53
and Ki67 expression in specimens of radical prostatectomy. Relationship
with clinico-pathologic data and survival]. Actas Urol Esp 24: 307 – 313
Ki-67 in conservatively treated prostate cancer
DM Berney et al
893
British Journal of Cancer (2009) 100(6), 888 – 893& 2009 Cancer Research UK
C
li
n
ic
a
l
S
tu
d
ie
s
